EpiSante Biomedical | DNA methylation analysis | cancer management

EpiSante Biomedical is a company that focuses on applying DNA methylation for cancer management, with professional knowledge, technical skills and extensive R&D experience.

The founder, Dr. Chang-Yi Lu, has been devoted to methylation research for 20 years.

In 2009, he established the "whole-genome DNA methylation analysis platform technology" at Industrial Technology Research Institute, and then led the R&D team to commercialize it, launching the first liver cancer early diagnostic kit using DNA methylation technology in Asia in 2018, successfully transferring the technology and non-exclusively licensing it to Phalanx Biotech in 2019, helping it establish a LDTs-certified laboratory.

EpiSante Biomedical launched the world's first DNA methylation testing services for the surgery prognosis and ablation monitoring products for the liver cancer in 2023. As the leader of DNA methylation technology in Taiwan, EpiSante Biomedical will integrate its years of research and development capabilities and clinical research experience, connect the upstream to downstream of precision medicine by using DNA methylation, and provide more accurate solutions for early cancer diagnosis, monitoring, and personalized treatments.